This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Lilly (LLY) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.
Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Eli Lilly (LLY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
by Arpita Dutt
2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.
Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE
by Zacks Equity Research
Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.
Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?
by Zacks Equity Research
We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.
Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
by Zacks Equity Research
We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Top Research Reports for January 24, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including American Express (AXP), Time Warner (TWX), and Eli Lilly (LLY).
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.
4 Drug Stocks Poised to Surprise this Earnings Season
by Zacks Equity Research
Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.
Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.
Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.
Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?
by Zacks Equity Research
We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
by Zacks Equity Research
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
Top Research Reports for 16th January, 2017
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Accenture (ACN) and Eli Lilly (LLY).
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.